NOTRELOAD AI
  • NOTRELOAD AI
  • Stocks BUZZ.
  • #TrumpTrade
  • 24-HOUR Pass →
  • Invest ↗
Sign in Subscribe

FDA Approves First Treatment for Rare Menkes Disease

ZYCUBO becomes the first FDA-approved treatment for Menkes disease, a rare genetic disorder affecting copper transport in children, offering new hope for patients.

FDA Approves First Treatment for Rare Menkes Disease
Credit: Fortress Biotech
Already have an account? Sign in.
01/13/2026 · 8:11 AM
FBIO
/ Don't stop with just one post.

Related↓

10/01/2025 · 9:12 AM

Fortress Biotech Stock Plummets After FDA Rejection

FDA rejected Fortress Biotech's Menkes drug, CUTX-101, due to factory issues, but the drug's safety and efficacy data were fine.

/ Subscriber only
/ Read more

Feed↓

Roblox Stock Upgraded to Buy as Growth Outlook Strengthens
02/09/2026 · 3:35 PM

Roblox Stock Upgraded to Buy as Growth Outlook Strengthens

Roth Capital upgrades Roblox to Buy with an $84 price target, citing strong bookings growth, improved game quality, and rising older player engagement.

/ Subscriber only
Trump Endorses Nexstar-Tegna $6.2B Merger After Reversal
02/09/2026 · 12:32 PM

Trump Endorses Nexstar-Tegna $6.2B Merger After Reversal

President Trump endorses Nexstar's $6.2B Tegna acquisition, reversing earlier criticism. Deal would create largest local TV operator covering 80% of U.S. households.

/ Subscriber only
Cleveland-Cliffs Extends POSCO Deal Timeline to H1 2026 Amid Q4 Losses
Featured/ 02/09/2026 · 12:10 PM

Cleveland-Cliffs Extends POSCO Deal Timeline to H1 2026 Amid Q4 Losses

Cleveland-Cliffs reports Q4 2025 losses but sees brighter 2026 outlook. POSCO partnership negotiations extended to first half 2026. Stock drops 19% on disappointing results.

/ Subscriber only
  • UP↑
  • Terms/Privacy
  • Sign up
  • Sign in
  • Discord
  • X
  • Bluesky
  • Telegram
  • Reach out →
  • Invest ↗
  • NOTRELOAD AI
DON'T FALL BEHIND. ©2025
Email address Subscribe